BRIEF—argenx and Halozyme to collaborate on drug delivery

Dutch firm argenx has partnered with US-based Halozyme Therapeutics to leverage the latter’s ENHANZE drug delivery tech.

Argenx aims to create multiple subcutaneous products based on current or future candidates, with the aim of reducing drug administration time. The deal includes the firm’s lead asset efgartigimod, plus up to two more.

Argenx will pay $30 million upfront, $10 million per target for future target nominations and up to $160 million per target based on development, regulatory and sales-based milestones. Halozyme will also receive mid-single digit royalties.